ArticleJournal of nuclear medicine : official publication, Society of Nuclear Medicine2009
Immunoimaging of CXCR4 expression in brain tumor xenografts using SPECT/CT.
Article in Journal of nuclear medicine : official publication, Society of Nuclear Medicine, 2009. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 39 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
39 citing papers in PubMed, 66 citations in OpenAlex.
- Advancing the understanding of tumor microenvironment through medical imaging based on bibliometric analysis.Translational cancer research · 2026Article
- Potential role ofAsia Oceania journal of nuclear medicine & biology · 2026Article
- CXCR4-targeted theranostics in oncology.European journal of nuclear medicine and molecular imaging · 2022Review
- The Role of [Cancers · 2022Review
- An Evaluation of CXCR4 Targeting with PAMAM Dendrimer Conjugates for Oncologic Applications.Pharmaceutics · 2022Article
- Investigating CXCR4 expression of tumor cells and the vascular compartment: A multimodal approach.PloS one · 2021Article
- Structural and Biological Characterizations of Novel High-Affinity Fluorescent Probes with Overlapped and Distinctive Binding Regions on CXCR4.Molecules (Basel, Switzerland) · 2019Article
- Selective depletion of metastatic stem cells as therapy for human colorectal cancer.EMBO molecular medicine · 2018Article
- Imaging CXCR4 Expression with (99m)Tc-Radiolabeled Small-Interference RNA in Experimental Human Breast Cancer Xenografts.Molecular imaging and biology · 2016Article
- A fully human CXCR4 antibody demonstrates diagnostic utility and therapeutic efficacy in solid tumor xenografts.Oncotarget · 2016Article
- Potential of CXCR4/CXCL12 Chemokine Axis in Cancer Drug Delivery.Current pharmacology reports · 2016Article
- In vivo molecular imaging of chemokine receptor CXCR4 expression in patients with advanced multiple myeloma.EMBO molecular medicine · 2015Article
- Structural characterization and in vivo evaluation of β-Hairpin peptidomimetics as specific CXCR4 imaging agents.Molecular pharmaceutics · 2015Article
- Disclosing the CXCR4 expression in lymphoproliferative diseases by targeted molecular imaging.Theranostics · 2015Article
- CXCR4-targeted and MMP-responsive iron oxide nanoparticles for enhanced magnetic resonance imaging.Angewandte Chemie (International ed. in English) · 2014Article
- Bridged cyclams as imaging agents for chemokine receptor 4 (CXCR4).Nuclear medicine and biology · 2014Article
- The role of preclinical SPECT in oncological and neurological research in combination with either CT or MRI.European journal of nuclear medicine and molecular imaging · 2014Review
- Imaging Axl expression in pancreatic and prostate cancer xenografts.Biochemical and biophysical research communications · 2014Article
- The intricate role of CXCR4 in cancer.Advances in cancer research · 2014Review
- Multimodality imaging of CXCR4 in cancer: current status towards clinical translation.Current molecular medicine · 2013Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors at 1 institution in 1 country.
Funding
Abstract
unlabelledChemokine receptor 4 (CXCR4) is expressed in a variety of cancers, including breast, brain, ovarian, and prostate. CXCR4-CXCL12 interactions are critical for tumor development, growth, and metastasis. Compared with normal tissue, neoplastic tissue (including metastases) expresses high levels of CXCR4. Previous clinical and preclinical observations suggest that CXCR4 levels could be used as a predictive marker of metastatic potential. Here we report the results of SPECT/CT of CXCR4 expression levels in experimental brain tumors using (125)I-labeled anti-CXCR4 monoclonal antibodies (mAbs).
methodshCXCR4 antibody 12G5 and control IgG(2A) antibody were radiolabeled. Radio-mAbs were obtained in 40%-60% yield, with 1.4-1.9 MBq/microg specific radioactivities and greater than 95% purity. Severe combined immunodeficient mice harboring U87 xenografts were used for ex vivo biodistribution and imaging studies. Surface CXCR4 expression levels on U87 tumor-derived cells were analyzed by flow cytometry.
resultsBiodistribution and imaging studies showed a specific accumulation of (125)I-12G5 in U87 tumors, with tumor-to-muscle uptake ratios reaching 15 +/- 3 at 48 h after injection. The tumor-to-tumor uptake ratio for (125)I-12G5 and (125)I-IgG(2A) was 2.5 at 48 h after injection. Flow cytometry analysis of tumor-derived cells showed a 2- to 7-fold increase in CXCR4 expression relative to inoculums, accounting for the high mAb uptake observed in the tumors.
conclusionOur data demonstrate the feasibility of imaging CXCR4 expression in experimental brain tumors. The elevated CXCR4 levels observed may have been, in part, due to the hypoxic tumor microenvironment.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.